Brokers Offer Predictions for Societal CDMO, Inc.’s FY2026 Earnings (NASDAQ:SCTL)

Societal CDMO, Inc. (NASDAQ:SCTLGet Rating) – Research analysts at William Blair reduced their FY2026 earnings estimates for Societal CDMO in a research note issued to investors on Thursday, November 10th. William Blair analyst M. Smock now forecasts that the company will earn $0.03 per share for the year, down from their previous forecast of $0.05. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Societal CDMO’s current full-year earnings is ($0.24) per share.

Societal CDMO Price Performance

SCTL stock opened at $1.67 on Monday. The stock has a 50-day moving average price of $1.57 and a two-hundred day moving average price of $1.16. Societal CDMO has a 1 year low of $0.62 and a 1 year high of $2.19. The stock has a market cap of $94.69 million, a PE ratio of -6.96 and a beta of 0.72. The company has a current ratio of 3.93, a quick ratio of 3.30 and a debt-to-equity ratio of 2.62.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SCTL. Prudential Financial Inc. acquired a new position in Societal CDMO during the 3rd quarter worth approximately $48,000. Russell Investments Group Ltd. bought a new stake in shares of Societal CDMO in the third quarter worth $487,000. Boston Partners bought a new stake in shares of Societal CDMO in the third quarter worth $150,000. Eagle Asset Management Inc. acquired a new position in Societal CDMO during the third quarter worth $59,000. Finally, Cowen Prime Advisors LLC bought a new position in Societal CDMO in the third quarter valued at $5,231,000. 58.15% of the stock is currently owned by institutional investors.

About Societal CDMO

(Get Rating)

Societal CDMO, Inc, a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.

Recommended Stories

Receive News & Ratings for Societal CDMO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Societal CDMO and related companies with MarketBeat.com's FREE daily email newsletter.